FDA management and enforcement: hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, first session, September 12, 1991, Volume 4
United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations
U.S. Government Printing Office, 1992 - Political Science - 388 pages
What people are saying - Write a review
We haven't found any reviews in the usual places.
Other editions - View all
action additional advertising Agency ANDA Work Group ANDA's approval process Astrue autoimmune disease Barr Laboratories Benson bioequivalence blockbuster drugs bovine collagen c/c valve carbamazepine CDER CDRH Center for Drug Chairman chemistry review chemists Chesemore collagen injections Commissioner compliance connective tissue diseases Counsel debarment developed Dingell Director Division DMFs document draft Drug Administration drug applications drug approval Drug Evaluation drug products Eckart effective enforcement Evaluation and Research FDA's files firms Food and Drug fraud policy Group Mtg hearing identified implemented industry initiatives inspection Inspector issues Kessler Kusserow labeling manufacturing manufacturing practices medical device patients pharmaceutical physicians PM/DM problems procedures question recommendation regulations regulatory request response review process Rowland Section seizure September 12 Shiley Shiley's specific staff strut fracture Subcommittee submitted thromboembolic zidovudine Zyderm